

LANCE[®] Ultra

Eu-W1024 labeled Anti-Phospho-DNA Topoisomerase 2-alpha

(Thr1342) Antibody

Product number:	TRF0218-D		Lot Number:	3318208	
					$\sqrt{}$
Product Format:	TRF0218-D: 10 μg				
	TRF0218-M: 100 μg				
Manufacturing date:	2/27/2024	Document version:	1		
Product Information					
Antibody:	Europium-labeled mouse monoclonal antibody recognizing human DNA Topoisomerase 2-alpha phosphorylated at Thr1342.				
Storage Buffer:	50 mM Tris-HCl (pH 7.4), 0.9% NaCl with 0.05% sodium azide as preservative and 0.1 % BSA				
Molecular Weight:	160 000				
Stability:	This product is stable for at least 18 months from the manufacturing date when stored in its original packaging and at the recommended storage conditions.				
Storage Conditions:	Store at 4°C				

Quality Control

The QC release specifications are based on spectrophotometric analysis of the labeled antibody. We certify that results meet our quality release criteria.

Labeling Ratio:	8.7 / 1
Concentration:	100 μg/mL (0.625 μM)

Recommended Assay Conditions

SUGGESTED METHOD:

(Specific applications might require optimization)

Reagent Preparation


- Prepare 1X Kinase Assay Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 10 mM MgCl₂, 2 mM DTT, 0.01% Tween-20 and 0.01% BSA.
- Prepare a 4X ULight-DNA Topoisomerase 2-alpha (Thr1342) Peptide solution: dilute ULight-DNA Topoisomerase 2-alpha (Thr1342) to a concentration of 200 nM in Kinase Assay Buffer.
- Prepare a 2X PLK3 solution: dilute enzyme to a concentration of 25 pM in Kinase Assay Buffer. Keep on ice.
- Prepare a 4X ATP solution: dilute ATP to concentrations ranging from 40 nM to 4 mM (serial half-log dilutions) in Kinase Assay Buffer. Keep on ice.
- Prepare 1X Detection Buffer: dilute 0.5 mL of 10X Detection Buffer with 4.5 mL of H₂O.
- Prepare a 4X Stop solution*: dilute EDTA to a concentration of 24 mM in 1X Detection Buffer.
- Prepare a 4X Detection Mix: dilute Europium-anti-phospho-DNA Topoisomerase 2-alpha (Thr1342) Antibody to a concentration of 8 nM in 1X Detection Buffer.


Protocol

- Pipet 5 μ L of 2X PLK3 solution (12.5 pM final concentration).
- Add 2.5 μL of 4X ULight-DNA Topoisomerase 2-alpha (Thr1342) Peptide solution into a 384-well white OptiPlate-384 (50 nM final concentration).
- Add 2.5 µL of 4X ATP solution (10 nM to 1 mM final concentrations).
- Cover plate with TopSeal-A and incubate 60 min at 23°C.
- Add 5 µL of 4X Stop solution* and incubate 5 min at 23°C.
- Add 5 μL of Detection Mix (2 nM Eu-anti-phospho-DNA Topoisomerase 2-alpha (Thr1342) Antibody final concentration).
- Cover plate with TopSeal-A and incubate 60 min at 23°C.
- Remove TopSeal-A and read in TR-FRET mode at 665 nm (excitation at 320 or 340 nm).

*Alternatively, the Stop solution and Detection Mix can be premixed and added together to the kinase reaction.

Typical Product Data





Suggested Materials

- Substrate: ULight[™]- Topo II[®] (Thr1342) Peptide
- Antibody: Eu- anti-P-Topo II^[2] (Thr1342)
- Kinase: PLK3
- Detection Buffer: LANCE[®] Detection Buffer, 10X
- Plate: OptiPlate[™]-384, white
- TopSeal[™]-A

Supplier Revvity Inc Revvity Inc Carna Biosciences Revvity Inc Revvity Inc Revvity Inc

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.

TRF0218-R Rev01

ſevvī

Revvity, Inc. 940 Winter Street Waltham, MA 02451 USA (800) 762-4000 www.revvity.com

For a complete listing of our global offices, visit www.revvity.com Copyright ©2023, Revvity, Inc. All rights reserved.